蒋莉
发布时间:2019-12-18        浏览次数:7459

蒋莉 副教授 同济大学上海国际知识产权学院

邮箱:jelly3636@hotmail.com

地址:四平路1239号同济大学衷和楼10楼


教育经历:

2009年9月-2014年12月英国Bangor University法学博士

2006年9月-2009年7月山东大学法律硕士

2002年9月-2006年7月北京科技大学生物技术理学学士

研究方向:

专利法、科技法、生物技术法、医事法

主要工作经历:

2019年5月-今,同济大学上海国际知识产权学院,副教授

2015年5月-2019年4月,苏州大学王健法学院,讲师

教学经历:

开设知识产权法、Intellectual Property and Biomedicine(英文)、专利法、专利实务等课程

海外经历:

2009年9月-2014年12月,英国班戈大学攻读博士学位

所获证书和荣誉:

2022年,罗莎琳德富兰克林科学奖(Rosalind Franklin Society Award in Science)

2017年,江苏省知识产权骨干人才

2016年,专利代理人资格

2009年,国家留学基金委资助攻读博士学位

2009年,班戈大学125周年奖学金、法学院奖学金

2008年,法律执业资格

社会兼职:

1.担任Journal of law and the Biosciences,Asia Pacific Law Review,Biosocieties,Journal of Bioethical inquiry, Stem Cell Translational Medicine,Pharmaceutical Patent Analys等SSCI/SCIE/CSSCI核心期刊审稿人。

担任New Genetic and Society期刊编辑顾问(Guest Advisor)

科学研究:

科研项目:

1. 主持人,基因编辑技术的全球治理研究(19SFB2058), 国家司法与法治理论研究课题,2019

2. 主持人,伦理困境下基因编辑法律问题研究(18CFX066),国家社会科学基金,2018

3. 主持人,基因编辑法律治理研究(2018T110535),中国博士后特别资助,2018

4. 主持人,人类基因编辑立法规制研究(CLS(2017)Y12),中国法学会,2017

5. 主持人,生物技术革命中专利伦理问题及其应对研究(17ZXC003),江苏省社会科学基金,2017

6. 主持人,技术发展中专利伦理问题研究(17SFB3028),国家司法与法治理论研究课题,2017

7. 主持人,知识产权法伦理规制研究(2016M590503),中国博士后基金会面上资助项目,2016

8. 主持人,知识产权法伦理问题研究,江苏省教育厅高校哲学社会科学研究项目,2016

9. 主要参与人,GenE-Type: A Biomedical, Ethical and Legal analysis of Modern Techniques of Genome Editing and its Potential Application, 德国联邦教育及研究部, 2017

部分出版物:

著作:

1.Li Jiang, Regulating Human Embryonic Stem Cell in China- A Comparative Study on Human Embryonic Stem Cell’s Patentability and Morality in US and EU, (2016), Springer (施普林格出版社)

论文:

1.蒋莉,《基因编辑植物法律规制的困境与出路》,载《法学》2023年第5期。(CSSCI)

2.Li Jiang and Hong Yang, “Generic Drugs and Innovative Drug Incentives: Early Dispute Resolution Mechanism in China” (2022) 41 Biotechnology Law Report 186-193. (SCIE)

3.Li Jiang, “14-Day limit of human embryo research: moral issues in the patent law in China” (2021) 40 Biotechnology Law Report 393-408. (SSCI)

4.Li Jiang, “Commercialization of the gene-edited crop and morality: challenges from liberal patent law and strict GMO law in the EU” (2020) 39 New Genetic and Society 191-218. (SSCI)

5.Li Jiang,“Alienation from the Objectives of the Patent System: How to Remedy the Situation of Biotechnology Patent” (2019) 25 Science and Engineering Ethic 791-811. (SSCI) 

6.Li Jiang and Achim Rosemann,“Human embryo gene editing in China: the uncertain legal status of the embryo”(2018)14 BioSocieties 46-66. (SSCI)

7.Li Jiang,“Centralised Intellectual Property Administrative Management Reform in China: Why it is needed and whether it works” (2018) 111 Intellectual Property Forum 19-24 

8.蒋莉,《基因编辑和人类生殖:社会伦理和法律规制》,《苏州大学学报法学版》,2018年第4期 

9.蒋莉,《人类基因编辑应有法可依》,载《中国社会科学报》2018年2月7日第1390期。

10.Achim Rosemann, Xin Qing Zhang and Li Jiang, “Human Germ Line Gene Editing: Why Comparative, Cross-National Studies of Public Viewpoints are Important” (2017) 5 Anthropology 175-178.

11.Li Jiang and Bing He Dong,“Fraudsters Operate and Officialdom Turns a Blind Eye: a Proposal for Controlling Stem Cell Therapy in China” (2016) 19 Medicine, Health Care and Philosophy 403-410. (SSCI)

12.Li Jiang , “Will Wild East End Scientific Feast-the First Administrative Measure on Clinical Stem Cell Research in China” (2016) 35 Biotechnology Law Report 27-35. (SCI)

13.Li Jiang , “Will Diversity Regulations Disadvantage Human Embryonic Stem Cell Research: a Comparison between EU and US” (2014) 25 Depaul Journal of Art, Technology and Intellectual Property Law 53-90.

14.Li Jiang , “Between Scylla and Charybdis: Patentability And Morality Related To Human Embryonic Stem Cells”(2015)6 American University Intellectual Property Brief 53-97.

15.Li Jiang and Wei Shi, “Space for Flexibility: Lessons from the European Union Harmonization Model in Human Embryonic Stem Cell Regulation” (2014) 97 Intellectual Property Forum 63-68. 

书的章节:

1.Li Jiang, “The Regulation of Genome Editing Technologies and New Methods of Germline Interventions in China” in Jochen Taupitz and Deuring Silvia (ed.) Rechtliche Aspekte der Genom-Editierung an der menschlichen Keimbahn, Springer (2019)

2.Li Jiang,“The Regulation of Clinical Stem Cell in China” in Phuc Pham & Achim Rosemann (ed.), Stem Cells in Clinical Application: Safety, Ethics and Regulation, Springer (2017)

3.Li Jiang,“Patentability of Human Embryo Stem Cell: A Comparative Analyse of Case WARF in United States and Europe” in H. B. Singh, A. Jha and C. Keswani (ed.), Intellectual Property Issues in Biotechnology, CABI (2016) 

咨询报告:

1.2017年,Nuffield Bioethics Committee(英国纳菲尔德生物伦理委员会), Achim Rosemann, Li Jiang and Xing Qing Zhang, The Regulatory and Legal Situation of Human Embryo, Gamete and Germ Line Gene Editing Research and Clinical Applications in the People’s Republic of China.